Monitor for any future conversion to a 13D filing, which would signal a shift from passive to activist intent. The 5.7% stake is below the 10% threshold that typically triggers heightened scrutiny.
Price Chart
Executive Summary
Acorn Bioventures, L.P. and related entities filed an amended Schedule 13G disclosing a combined beneficial ownership of 1,284,221 shares (5.7%) of Karyopharm Therapeutics Inc., as of September 22, 2026. This is a passive stake filing with no indication of activist intent. The filing updates prior disclosures but does not provide a comparison to the previous filing's stake size, making the direction of change unclear.
Key Financial Metrics
Key Facts
- Acorn Bioventures, L.P. beneficially owns 539,373 shares (2.4%) of Karyopharm Therapeutics Inc.
- Acorn Bioventures 2, L.P. beneficially owns 744,848 shares (3.3%).
- Anders Hove, as manager of the general partners, may be deemed to beneficially own 1,284,221 shares (5.7%) in aggregate.
- The filing is an amendment to a Schedule 13G, indicating passive investment intent.
- Percentage calculated based on 22,681,460 shares outstanding as of June 30, 2026.
Financial Impact
No financial figures disclosed beyond share counts and percentages.
Risk Factors
- Passive filing — no indication of activist intent or catalyst for change.
- Stake size is modest and may not influence corporate actions.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001636587-26-000083 |
| Document: 0001636587-26-000083-index.html | 0001636587-26-000083 |
| Document: 0001636587-26-000083.txt | 0001636587-26-000083 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.5175 | awaiting T+60 | — | $0.4800 (+7.25%) |
Oct 14, 2026 13d ago | 8-K | $0.3150 | awaiting T+60 | — | $0.4800 (+52.38%) |
Oct 8, 2026 19d ago | SC 13G/A | $0.6000 | awaiting T+60 | — | $0.4800 (+20.00%) |
Sep 25, 2026 4w ago | SC 13G/A | $1.62 | awaiting T+60 | — | $0.4800 (−70.37%) |
Sep 25, 2026 4w ago | SC 13G/A | $1.62 | awaiting T+60 | — | $0.4800 (−70.37%) |
Sep 11, 2026 6w ago | 8-K | $1.61 | awaiting T+60 | — | $0.4800 (+70.19%) |
Aug 31, 2026 8w ago | 8-K | $2.06 | awaiting T+60 | — | $0.4800 (−76.70%) |
Aug 13, 2026 10w ago | 8-K | $1.99 | awaiting T+60 | — | $0.4800 (+75.88%) |
Aug 10, 2026 11w ago | Press Release | $1.96 | awaiting T+60 | — | $0.4800 (−75.51%) |
Jul 31, 2026 12w ago | 8-K | $1.92 $0.4821 | ▼ −74.89% | ▼ −77.35% | $0.4800 (−75.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers